Earnings call transcript: Loblaw Q4 2025 sees revenue growth, stock dips

Loblaw reported Q4 EPS of CAD 0.67, beating the CAD 0.6573 consensus (+1.93% surprise), while revenue of CAD 16.61B missed the CAD 16.7B estimate (-0.54%), and the stock fell 5.05% pre-market to CAD 64.11. Operational highlights included 3.5% 12-week revenue growth (11.0% including the extra week), CAD 1.8B adjusted EBITDA (+4.8%), retail gross margin up 10bps to 31.0%, CAD 4.5B+ online sales (digital +19.6% in Q4), and continued store expansion and automation investments. Management guided FY2026 EPS to CAD 8.14 and revenue to CAD 19.1B, plans ~CAD 2.4B CapEx, ~CAD 1.9B share repurchases, and noted the planned sale of PC Financial to EQ Bank; fundamentals look constructive despite the near-term revenue miss and negative market reaction.

Analysis

Loblaw’s playbook is shifting the profit center, not just sales mix: third-party delivery plus faster automation materially compresses the historical e‑commerce drag by turning fulfilment into an outsourced, variable cost instead of a fixed one. That structural change amplifies the value of store expansion (especially small-format discount stores) because each incremental online order now contributes positively to store productivity instead of cannibalizing margins — a multi‑quarter re‑rating mechanism if execution stays on plan.

The EQB transaction is the hidden operational lever. If EQB scales credit‑card issuance as planned, the loyalty flywheel (higher card penetration → higher basket frequency) will outsizedly lift Loblaw’s same‑store economics over 12–24 months; conversely, regulatory or closing delays are the single largest near‑term binary risk. A faster‑than‑expected GLP‑1 genericization (probable over the next 6–12 months) is the clearest downside catalyst for pharmacy profit growth and will compress headline multiple expansion if not offset by stronger retail gross margin gains.

Market reaction appears to have priced near‑term execution noise rather than durable optionality: the combination of predictable buybacks, sizable free‑cash conversion optionality from automation, and a loyalty acceleration via EQB implies asymmetric upside vs. the principal risks (deal timing, DC ramp glitches, drug generic timing). Time horizon matters — days are dominated by headline misses; months to a year are when DC productivity, card issuance cadence and GLP‑1 timing resolve and re‑rate the name.

Key Decisions for Investors

• L.TO — Core long (6–12 month horizon): Establish a position sized to 3–5% of equity sleeve. Target +20–30% upside driven by automated DC productivity and buybacks; place a tactical stop at −12% to limit drawdown from deal/timing risk. Consider replacing part of the outright with a Jan‑2027 bull call spread to cap downside with defined cost.
• EQB.TO — Event/merger arbitrage (9–18 month horizon): Buy ahead of close on the expectation of faster card issuance and higher NIM; asymmetric payoff if EQB executes. Size modestly (<2% portfolio) given regulatory/close timing risk; stop if acquisition timeline slips beyond 6 months or guidance is materially reduced.
• GOOGL / GOOG — Strategic long (12–24 months): Buy exposure to capture monetization upside from retail integrations (search-to-purchase, retail media placements). Target total return 15–25%; hedge broadly cyclical risk by pairing with a small protective put position on L.TO if worried about retail macro.
• Hedge / Protection — Tactical put hedge on L.TO (3–6 month): Buy near‑dated puts (~6–8% OTM) to protect during the window of PC Financial close and GLP‑1 generic uncertainty. Cost of hedge should be treated as insurance against the two highest‑impact binary events; reduce hedge as milestones (deal close, GLP‑1 clarity, DC ramp metrics) are met.